{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:34:28Z","timestamp":1767652468996,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s12325-021-01632-x","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T12:42:00Z","timestamp":1612528920000},"page":"1614-1626","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials"],"prefix":"10.1007","volume":"38","author":[{"given":"Dulanji K.","family":"Kuruppu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"North","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy J.","family":"Kovacik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric M.","family":"Pearlman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan L.","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"1632_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343\u20139.","journal-title":"Neurology"},{"key":"1632_CR2","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"1632_CR3","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators","year":"2017","unstructured":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211\u201359.","journal-title":"Lancet"},{"key":"1632_CR4","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/head.12550","volume":"55","author":"WJ Becker","year":"2015","unstructured":"Becker WJ. Acute migraine treatment in adults. Headache. 2015;55:778\u201393.","journal-title":"Headache"},{"issue":"Suppl 2","key":"1632_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/head.12505_2","volume":"55","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;55(Suppl 2):103\u201322.","journal-title":"Headache"},{"key":"1632_CR6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37:470\u201385.","journal-title":"Cephalalgia"},{"key":"1632_CR7","first-page":"45","volume":"25","author":"JH Ford","year":"2019","unstructured":"Ford JH, Schroeder K, Nyhuis AW, Foster SA, Aurora SK. Cycling through migraine preventive treatments: implications for all-cause total direct costs and disease-specific costs. J Manag Care Spec Pharm. 2019;25:45\u201359.","journal-title":"J Manag Care Spec Pharm"},{"key":"1632_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"American Headache Society","year":"2019","unstructured":"American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1\u201318.","journal-title":"Headache"},{"key":"1632_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4103\/0972-2327.182302","volume":"19","author":"R Malhotra","year":"2016","unstructured":"Malhotra R. Understanding migraine: potential role of neurogenic inflammation. Ann Indian Acad Neurol. 2016;19:175\u201382.","journal-title":"Ann Indian Acad Neurol"},{"key":"1632_CR10","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s13311-018-0622-7","volume":"15","author":"B Raffaelli","year":"2018","unstructured":"Raffaelli B, Reuter U. The biology of monoclonal antibodies: focus on calcitonin gene-related peptide for prophylactic migraine therapy. Neurotherapeutics. 2018;15:324\u201335.","journal-title":"Neurotherapeutics"},{"key":"1632_CR11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/WCO.0000000000000548","volume":"31","author":"K Paemeleire","year":"2018","unstructured":"Paemeleire K, MaassenVanDenBrink A. Calcitonin-gene-related peptide pathway mAbs and migraine prevention. Curr Opin Neurol. 2018;31:274\u201380.","journal-title":"Curr Opin Neurol"},{"key":"1632_CR12","unstructured":"Emgality\u2122 (galcanezumab-gnlm) [package insert]. Indianapolis: Eli Lilly and Company; 2019."},{"key":"1632_CR13","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75:1080\u20138.","journal-title":"JAMA Neurol"},{"key":"1632_CR14","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38:1442\u201354.","journal-title":"Cephalalgia"},{"key":"1632_CR15","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91:e2211\u201321.","journal-title":"Neurology"},{"key":"1632_CR16","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629\u2013808.","DOI":"10.1177\/0333102413485658"},{"key":"1632_CR17","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337\u201345.","journal-title":"Neurology"},{"key":"1632_CR18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/head.13691","volume":"60","author":"HC Detke","year":"2020","unstructured":"Detke HC, Millen BA, Zhang Q, et al. Rapid onset of effect of galcanezumab for the prevention of episodic migraine: analysis of the EVOLVE studies. Headache. 2020;60:348\u201359.","journal-title":"Headache"},{"key":"1632_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s10194-018-0951-2","volume":"19","author":"S F\u00f6rderreuther","year":"2018","unstructured":"F\u00f6rderreuther S, Zhang Q, Stauffer VL, Aurora SK, L\u00e1inez MJA. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. J Headache Pain. 2018;19:121.","journal-title":"J Headache Pain"},{"key":"1632_CR20","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/head.13508","volume":"59","author":"VL Stauffer","year":"2019","unstructured":"Stauffer VL, Wang S, Voulgaropoulos M, Skljarevski V, Kovacik A, Aurora SK. Effect of galcanezumab following treatment cessation in patients with migraine: results from 2 randomized phase 3 trials. Headache. 2019;59:834\u201347.","journal-title":"Headache"},{"key":"1632_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0333102411430849","volume":"32","author":"P Tfelt-Hansen","year":"2012","unstructured":"Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012;32:6\u201338.","journal-title":"Cephalalgia"},{"key":"1632_CR22","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","volume":"27","author":"HC Diener","year":"2007","unstructured":"Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814\u201323.","journal-title":"Cephalalgia"},{"key":"1632_CR23","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026\u201337.","journal-title":"Cephalalgia"},{"key":"1632_CR24","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/jnnp-2013-307149","volume":"86","author":"SD Silberstein","year":"2015","unstructured":"Silberstein SD, Dodick DW, Aurora SK, et al. Percent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry. 2015;86:996\u20131001.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1632_CR25","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1526-4610.2007.00757.x","volume":"47","author":"MFP Peres","year":"2007","unstructured":"Peres MFP, Silbertstein S, Moreira F, et al. Patients\u2019 preference for migraine preventive therapy. Headache. 2007;47:540\u20135.","journal-title":"Headache"},{"key":"1632_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20:6.","journal-title":"J Headache Pain"},{"key":"1632_CR27","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1179\/1743132813Y.0000000244","volume":"35","author":"SK Bhoi","year":"2013","unstructured":"Bhoi SK, Kalita J, Misra UK. Is 6 months of migraine prophylaxis adequate? Neurol Res. 2013;35:1009\u201314.","journal-title":"Neurol Res"},{"key":"1632_CR28","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1177\/0333102419840780","volume":"39","author":"W Kielbasa","year":"2019","unstructured":"Kielbasa W, Helton D. A new era for migraine: pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia. 2019;39:1284\u201397.","journal-title":"Cephalalgia"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01632-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-021-01632-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01632-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T11:21:49Z","timestamp":1697800909000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-021-01632-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1632"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01632-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2021,2,5]]},"assertion":[{"value":"2 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}